Trial reportWorld journal of gastroenterology2016
Beneficial effects of antidepressant mirtazapine in functional dyspepsia patients with weight loss.
Trial report in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 52 citations in OpenAlex.
- Effects of Low-Dose Amitriptyline on Epigastric Pain Syndrome in Functional Dyspepsia Patients.Digestive diseases and sciences · 2021Trial
- The Role of Diet in Functional Dyspepsia.Nutrients · 2026Review
- Mirtazapine in Treating Functional Dyspepsia: A Systematic Review and Meta-Analysis.Gastroenterology research · 2026Article
- Mirtazapine for the treatment of irritable bowel syndrome: A systematic review.World journal of methodology · 2026Article
- Insights Into Functional Dyspepsia and Gastroparesis - Western Versus Asian Perspectives.Journal of neurogastroenterology and motility · 2025Review
- Mirtazapine Is Associated With Shorter Hospital Stay in Pediatric Avoidant Restrictive Food Intake Disorder-A Retrospective Chart Review.The International journal of eating disorders · 2025Article
- Randomized clinical trial: the effects of mirtazapine in functional dyspepsia patients.Therapeutic advances in gastroenterology · 2025Article
- Brief cognitive-behavioral treatment for avoidant/restrictive food intake disorder in the context of functional dyspepsia: Study protocol for a feasibility randomized controlled trial.Contemporary clinical trials · 2023Article
- Development of a brief cognitive-behavioral treatment for avoidant/restrictive food intake disorder in the context of disorders of gut-brain interaction: Initial feasibility, acceptability, and clinical outcomes.The International journal of eating disorders · 2023Observational
- Pharmacological Treatment of Functional Dyspepsia: An Old Story Revisited or a New Story to Be Told? A Clinical Review.GE Portuguese journal of gastroenterology · 2023Review
- Motilin and its receptor are expressed in the dorsal horn in a rat model of acute incisional pain: Intrathecal motilin injection alleviates pain behaviors.Frontiers in neuroscience · 2023Article
- Effect of Mirtazapine on Nausea in Children with Functional Nausea and Functional Dyspepsia Postprandial Distress Syndrome.Paediatric drugs · 2022Article
- Gut Hormones as Potential Therapeutic Targets or Biomarkers of Response in Depression: The Case of Motilin.Life (Basel, Switzerland) · 2021Review
- United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia.United European gastroenterology journal · 2021Article
- A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome.BioPsychoSocial medicine · 2021Article
- The Key Ingredient Acacetin in Weishu Decoction Alleviates Gastrointestinal Motility Disorder Based on Network Pharmacology Analysis.Mediators of inflammation · 2021Article
- Functional Dyspepsia: A Review of the Symptoms, Evaluation, and Treatment Options.Gastroenterology & hepatology · 2020Article
- Precise and systematic survey of the efficacy of multicomponent drugs against functional dyspepsia.Scientific reports · 2019Article
- Immunopathological and molecular basis of functional dyspepsia and current therapeutic approaches.Expert review of clinical immunology · 2018Review
- "First Do No Harm": Adverse Events from Pharmaceutical Treatment of Gastroparesis and Dyspepsia.Digestive diseases and sciences · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo explore the effects and mechanism of action of antidepressant mirtazapine in functional dyspepsia (FD) patients with weight loss.
methodsSixty depressive FD patients with weight loss were randomly divided into a mirtazapine group (MG), a paroxetine group (PG) or a conventional therapy group (CG) for an 8-wk clinical trial. Adverse effects and treatment response were recorded. The Nepean Dyspepsia Index-symptom (NDSI) checklist and the 17-item Hamilton Rating Scale of Depression (HAMD-17) were used to evaluate dyspepsia and depressive symptoms, respectively. The body composition analyzer was used to measure body weight and fat. Serum hormone levels were measured by ELISA.
results(1) After 2 wk of treatment, NDSI scores were significantly lower for the MG than for the PG and CG; (2) After 4 or 8 wk of treatment, HAMD-17 scores were significantly lower for the MG and PG than for the CG; (3) After 8 wk of treatment, patients in the MG experienced a weight gain of 3.58 ± 1.57 kg, which was significantly higher than that observed for patients in the PG and CG. Body fat increased by 2.77 ± 0.14 kg, the body fat ratio rose by 4%, and the visceral fat area increased by 7.56 ± 2.25 cm(2); and (4) For the MG, serum hormone levels of ghrelin, neuropeptide Y (NPY), motilin (MTL) and gastrin (GAS) were significantly upregulated; in contrast, those of leptin, 5-hydroxytryptamine (5-HT) and cholecystokinin (CCK) were significantly downregulated.
conclusionMirtazapine not only alleviates symptoms associated with dyspepsia and depression linked to FD in patients with weight loss but also significantly increases body weight (mainly the visceral fat in body fat). The likely mechanism of mirtazapine action is regulation of brain-gut or gastrointestinal hormone levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.